Term ended Oct 25, 2026 · High confidence
20-year base term ended Oct 25, 2026
Held by Merck Sharp & Dohme LLC
Filed May 24, 2012 as application 13/479,622 · Granted Nov 12, 2013
Base term, 20 years from filing
Today
Term ended Oct 25, 2026
2006
2026
Clock starts
Oct 25, 2006
Oct 25, 2006
Term ended
Oct 25, 2026
Oct 25, 2026
Granted
Nov 12, 2013
Nov 12, 2013
base term
after the term ends
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,538,110, to Oct 25, 2026. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 25, 2006, when application 11/552,827, the earliest non-provisional in its chain, was filed (this one was filed May 24, 2012) | Oct 25, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,538,110) | resolves to Oct 25, 2026, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Oct 25, 2026 | High confidence |
Partial family
| US 7,538,110 | In force Apr 2027 | Apr 2027 |
| US 8,278,323 | In force Nov 2027 | Nov 2027 |
| US 8,580,788 | this patent Oct 2026 | Oct 2026 |
| Application 13/950,853 | No file history here not computed | not computed |
| US 8,895,560 | Term ended no later than Oct 2026 | no later than Oct 2026 |
Partial: 1 of the 5 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 20, 2012 Reel 29339, frame 669 | Cubist Pharmaceuticals, Inc.; Adolor Corporation; Calixa Therapeutics, Inc.; Cubist Pharmaceuticals Holdings, Inc.; Cubist Pharmaceuticals U.S. | Royal Bank of Canada, as Administrative Agent | Security Agreement |
| Jul 9, 2015 Reel 36046, frame 153 | Adolor Corporation | Merck Sharp & Dohme Corp. | Nunc Pro Tunc Assignment |
| Jul 24, 2015 Reel 36180, frame 70 | Royal Bank of Canada, as Administrative Agent | Calixa Therapeutics, Inc.; Adolor Corporation; Cubist Pharmaceuticals, Inc. | Release of Security Interest |
| Jul 24, 2015 reel/frame not recorded | Royal Bank of Canada, as Administrative Agent | Calixa Therapeutics, Inc. | Release of Security Interest |
| Jul 24, 2015 reel/frame not recorded | Royal Bank of Canada, as Administrative Agent | Adolor Corporation | Release of Security Interest |
| Jul 24, 2015 reel/frame not recorded | Royal Bank of Canada, as Administrative Agent | Cubist Pharmaceuticals, Inc. | Release of Security Interest |
| Aug 8, 2022 Reel 61102, frame 145 | Merck Sharp & Dohme Corp. | Merck Sharp & Dohme LLC | Merger |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,538,110, ends no earlier than this term, so it caps nothing.
Citations
2
later US patents cite this one
That is below the median of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.